eHealth Initiative

ehidc.org

eHealth Initiative and Foundation (eHI) is a Washington DC-based, independent, non-profit organization whose mission is to drive improvements in the quality, safety, and efficiency of healthcare through information technology. eHI is a multi-stakeholder collaborative, convening executives from every group in healthcare, to discuss, identify, and share best practices that transform the delivery of healthcare. Working with its membership, eHI advocates for the use of health IT that is practical, sustainable, and addresses stakeholder needs, particularly those of patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMA TECH

USP INTRODUCES ANALYTICAL R&D TO OPTIMIZE CONTINUOUS MANUFACTURING TECHNOLOGIES

US Pharmacopeia | January 04, 2023

news image

The United States Pharmacopeia (USP) has announced the launch of the USP Advanced Manufacturing Technology Lab in Richmond, Virginia, as a part of its launch of a suite of R&D analytical solutions. These analytical lab services will aid drug manufacturers in adopting advanced manufacturing technologies, such as pharmaceutical continuous manufacturing (PCM), to increase geographic diversity in pharmaceutical manufacturing and support medicine supply chain resilience. The new R&...

Read More

TAKEDA, DEBT IN MIND, OFFLOADS 18 DRUGS IN ASIA PACIFIC TO CELLTRION FOR $278M

Fiercepharma | June 11, 2020

news image

Takeda has earmarked another chunk of business for divestment to help it pay down debt. The Japanese pharma is offloading 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea’s Celltrion for $278 million, it said on Thursday. The portfolio generated sales of about $140 million in the fiscal year ended in March 2019, mainly driven by DPP-4 diabetes drug Nesina and hypertension med Edarbi, Takeda said. It will continue to manufacture the products and ...

Read More

Business Insights

TREATMENT TO EXPAND GLOBAL LIBRARY OF MEDICINE WITH DERMATOLOGIC DISEASES

Treatment.com International Inc. | January 05, 2022

news image

Treatment.com International Inc. a healthcare AI technology company, has entered into a research project agreement with the University of Minnesota to add more than 220 dermatologic diseases to their proprietary, responsive AI engine known as the Global Library of Medicine (GLM). The addition of these diagnoses will bring another level of accuracy and specificity to the GLM, enhancing soon-to-be-released products such as the Treatment Mobile app, which is set for release this month.
Read More

Business Insights, PHARMA TECH

INNATE PHARMA ANNOUNCES PRECLINICAL DATA PUBLICATION IN NATURE BIOTECHNOLOGY

Innate Pharma | January 17, 2023

news image

On January 16, 2023, Innate Pharma SA announced the publication of preclinical findings demonstrating the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123 in the scientific journal Nature Biotechnology. Innate and Sanofi conducted the experiments, which were published in Nature Biotechnology on January 12, 2023. This study demonstrates that CD64 expression on AML blasts imparts resistance to anti-CD123 antibody-d...

Read More
news image

Business Insights, PHARMA TECH

USP INTRODUCES ANALYTICAL R&D TO OPTIMIZE CONTINUOUS MANUFACTURING TECHNOLOGIES

US Pharmacopeia | January 04, 2023

The United States Pharmacopeia (USP) has announced the launch of the USP Advanced Manufacturing Technology Lab in Richmond, Virginia, as a part of its launch of a suite of R&D analytical solutions. These analytical lab services will aid drug manufacturers in adopting advanced manufacturing technologies, such as pharmaceutical continuous manufacturing (PCM), to increase geographic diversity in pharmaceutical manufacturing and support medicine supply chain resilience. The new R&...

Read More
news image

TAKEDA, DEBT IN MIND, OFFLOADS 18 DRUGS IN ASIA PACIFIC TO CELLTRION FOR $278M

Fiercepharma | June 11, 2020

Takeda has earmarked another chunk of business for divestment to help it pay down debt. The Japanese pharma is offloading 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea’s Celltrion for $278 million, it said on Thursday. The portfolio generated sales of about $140 million in the fiscal year ended in March 2019, mainly driven by DPP-4 diabetes drug Nesina and hypertension med Edarbi, Takeda said. It will continue to manufacture the products and ...

Read More
news image

Business Insights

TREATMENT TO EXPAND GLOBAL LIBRARY OF MEDICINE WITH DERMATOLOGIC DISEASES

Treatment.com International Inc. | January 05, 2022

Treatment.com International Inc. a healthcare AI technology company, has entered into a research project agreement with the University of Minnesota to add more than 220 dermatologic diseases to their proprietary, responsive AI engine known as the Global Library of Medicine (GLM). The addition of these diagnoses will bring another level of accuracy and specificity to the GLM, enhancing soon-to-be-released products such as the Treatment Mobile app, which is set for release this month.
Read More

news image

Business Insights, PHARMA TECH

INNATE PHARMA ANNOUNCES PRECLINICAL DATA PUBLICATION IN NATURE BIOTECHNOLOGY

Innate Pharma | January 17, 2023

On January 16, 2023, Innate Pharma SA announced the publication of preclinical findings demonstrating the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123 in the scientific journal Nature Biotechnology. Innate and Sanofi conducted the experiments, which were published in Nature Biotechnology on January 12, 2023. This study demonstrates that CD64 expression on AML blasts imparts resistance to anti-CD123 antibody-d...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us